SRPT Sarepta Therapeutics Dashboard

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of the end of 2019, the company has two approved drugs . Sarepta started in Corvallis, Oregon on January 1, 1980 and was originally named Antivirals Inc. After occupying several research laboratory spaces in Corvallis, the company opened a production laboratory in Corvallis in February 2002 and was renamed AVI BioPharma Inc. The company made headlines in 2003 when it announced work on treatments for severe acute respiratory syndrome and the West Nile virus. In July 2009, the company announced they would move their headquarters from Portland, Oregon, north to Bothell, Washington, near Seattle. At that time, the company led by president and CEO Leslie Hudson had 83 employees and quarterly revenues of $3.2 million. AVI had yet to turn a profit and had not yet developed any commercial products as of July 2009. The company lost $19.7 million in the second quarter of 2009, and then won an $11.5 million contract with the U.S. Department of Defense's Defense Threat Reduction Agency in October 2009. By this time, the company had completed its headquarters move to Bothell.

Company profile

Ticker

SRPT

Exchange

NASDAQ

Website

www.sarepta.com/

CEO

Douglas Ingram

Incorporated

Delaware

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...

Former names

ANTIVIRALS INC, AVI BIOPHARMA INC

SEC CIK

0000873303

Corporate docs

Articles of Incorporation & Bylaws

IRS number

930797222

SRPT stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Stocks That Hit 52-Week Lows On Monday

12 Apr 21

Before 10 a.m. ET on Monday, 30 stocks hit new 52-week lows.

The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO

31 Mar 21

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 30)

Stocks That Hit 52-Week Lows On Tuesday

30 Mar 21

Before 10 a.m. ET on Tuesday, 50 stocks hit new 52-week lows.

The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings

30 Mar 21

The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs

26 Mar 21

Press releases

Pro users get this 30m faster

Sarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program

23 Mar 21

-- Application website is now open for the 2021 Scholarship Program -- -- The Company will award up to 15 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy -- CAMBRIDGE, Mass., March 23,

Sarepta Therapeutics' Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration

18 Mar 21

-- Protein expression in muscle was sustained for two years following treatment in the low dose cohort, with mean beta-sarcoglycan expression of 54% at 24 months, compared to 36% at Day 60, as measured by western blot

AavantiBio Bolsters Leadership Team with Appointment of Ty Howton as Chief Operating Officer and General Counsel

11 Mar 21

Industry Veteran Brings Over 20 Years of Commercial, Operational, and Legal Experience AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments

1 Mar 21

Sarepta Therapeutics, Inc. to Host Earnings Call

1 Mar 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

1 Mar 21

13 Apr 21

31 Dec 21

Financial summary

Financial statements Chart SRPT financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	1.51B	1.51B	1.51B	1.51B	1.51B	1.51B
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	62.83M	54.48M	58.18M	(positive/no burn)
Cash used (since last report)	n/a	n/a	215.73M	187.05M	199.76M	n/a
Cash remaining	n/a	n/a	1.3B	1.32B	1.31B	n/a
Runway (months of cash)	n/a	n/a	20.6	24.3	22.6	n/a

Beta Read what these cash burn values mean

Recent insider trades

SRPT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
10 Mar 21	M Kathleen Behrens	Common Stock	Sell	Dispose S	No	No	85.76	5,000	428.8K	130,517
10 Mar 21	M Kathleen Behrens	Common Stock	Option exercise	Aquire M	No	No	42.3	5,000	211.5K	135,517
10 Mar 21	M Kathleen Behrens	Stock Option Common Stock	Option exercise	Dispose M	No	No	42.3	5,000	211.5K	0
8 Mar 21	Hans Lennart Rudolf Wigzell	Common Stock	Sell	Dispose S	No	No	83.51	10,000	835.1K	16,518
8 Mar 21	Hans Lennart Rudolf Wigzell	Common Stock	Option exercise	Aquire M	No	No	34.92	10,000	349.2K	26,518
8 Mar 21	Hans Lennart Rudolf Wigzell	Stock Option Common Stock	Option exercise	Dispose M	No	No	34.92	10,000	349.2K	0
3 Mar 21	Barry Richard	Common Stock	Grant	Aquire A	No	No	0	2,726	0	3,125,366
3 Mar 21	Barry Richard	Stock Option Common Stock	Grant	Aquire A	No	No	87.11	5,518	480.67K	5,518
3 Mar 21	M Kathleen Behrens	Common Stock	Grant	Aquire A	No	No	0	2,726	0	130,517
3 Mar 21	M Kathleen Behrens	Stock Option Common Stock	Grant	Aquire A	No	No	87.11	5,518	480.67K	5,518

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

SRPT institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

88.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	446	404	+10.4%
Opened positions	87	51	+70.6%
Closed positions	45	55	-18.2%
Increased positions	122	131	-6.9%
Reduced positions	156	140	+11.4%

13F shares	Current	Prev Q	Change
Total value	17.35B	9.92B	+74.9%
Total shares	70.24M	70.68M	-0.6%
Total puts	3.47M	2.36M	+47.1%
Total calls	3.44M	1.99M	+73.1%
Total put/call ratio	1.0	1.2	-15.0%

Largest owners	Shares	Value	Change
Capital Research Global Investors	7.74M	$1.32B	+15.3%
Vanguard	7.22M	$1.23B	+1.8%
FMR	6.03M	$1.03B	-4.9%
BLK Blackrock	5.38M	$917.1M	-1.4%
JHG Janus Henderson	3.88M	$660.76M	-1.9%
Jennison Associates	2.43M	$413.93M	-6.8%
STT State Street	1.86M	$316.95M	-2.1%
Avoro Capital Advisors	1.75M	$298.36M	+4.5%
AMP Ameriprise Financial	1.6M	$272.4M	+3.2%
IVZ Invesco	1.44M	$245.74M	+31.6%

Largest transactions	Shares	Bought/sold	Change
Capital Research Global Investors	7.74M	+1.03M	+15.3%
Sands Capital Management	977.14K	-888.33K	-47.6%
Adage Capital Partners GP, L.L.C.	300K	-550K	-64.7%
Norges Bank	467.75K	+467.75K	NEW
Fred Alger Management	10.64K	-405.49K	-97.4%
JPM JPMorgan Chase & Co.	754.6K	-371.91K	-33.0%
IVZ Invesco	1.44M	+346.42K	+31.6%
FMR	6.03M	-309.31K	-4.9%
Logos Global Management	0	-275K	EXIT
Carillon Tower Advisers	263.3K	+263.3K	NEW

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Pfizer • PTC • Biogen • Vertex Pharmaceuticals • Arrowhead Pharmaceuticals • Alexion Pharmaceuticals • Roche • FibroGen • Shire • PTC Therapeutics

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Aid, amino, analogized, analogy, Arrowhead, assigned, attack, Azar, Biden, Bratica, brightest, buy, campaign, career, caregiving, Chair, childcare, CIFFREO, codenamed, Codiak, constitutionality, contractor, custody, cut, defraud, depict, depiction, devastate, diagnostic, diminish, distancing, driver, ELEVATE, enjoined, ensue, Estepan, ethnic, ethnicity, expenditure, faithfully, fear, Florida, formulary, Fulcrum, gender, GVP, Hansa, Harbor, hearing, heterogeneity, Ian, infection, intermittent, IP, JAMA, join, Joseph, JSC, lawsuit, leadership, learning, magnitude, mg, mission, mix, Neurology, nonperformance, onsite, pandemic, Pennsylvania, pension, predominant, prioritize, racial, reallocate, RegenX, regenxbio, remote, remotely, representation, resilience, rewarding, Selecta, Shield, spread, standalone, strength, sublicense, sweeping, talent, telehealth, terrorism, tuition, Ultragenyx, unclear, unemployment, unremitted, unwilling, urgent, Vifor, viltepso, visit, widespread, women

Removed: al, arose, Bonney, clinic, constantly, dismissal, doubtful, enzyme, Gilead, Interbank, leasing, LIBOR, line, London, Mahatme, Michael, MidCap, mortgage, motion, North, placebo, plaintiff, producing, putative, rental, revision, revolving, Sandesh, SAR, schema, selection, South, Summit, Tivorsan, trust, underway, utrophin, William

From filing 10-K 2020 FY